SYK Stryker Corporation
$293.78▼ -5.76%
Healthcare
Other
Volume 4.05M
Avg Volume (10D) 2.64M
Key Metrics & Fundamentals
Market Cap
$112.69B
P/E Ratio
30.4
Div Yield
1.13%
52W Range
267.00 - 389.33
% vs 50 MA
6.25%
% vs 200 MA
-3.83%
RSI-14
65.0
MACD Histogram
+2.6500
Beta (1Y vs SPY)
0.10
Free Cash Flow
$1.06B
Gross Rev
$6.59B
Gross Profit
$4.50B
EBITDA
$2.00B
COGS
$2.09B
Operating Exp
$2.84B
Operating Income
$1.66B
EBIT
$1.66B
Pretax Income
$1.56B
Net Income
$1.28B
EPS (Diluted)
3.30
Price & Volume History
Loading chart…
Recent News
Stryker's Q3 Miss Expected, But Negative Tone on Underperformance Unexpected, Truist Says
MT Newswires · Oct 30, 2026 2:57 PM ET
SYK Stock Skids as Q3 Earnings and Sales Miss & 2026 Outlook Cut
Zacks · Oct 30, 2026 1:56 PM ET
Truist Adjusts Price Target on Stryker to $305 From $310
MT Newswires · Oct 30, 2026 11:15 AM ET
Stryker (SYK) Q3 2026 Earnings Call Transcript
Motley Fool · Oct 30, 2026 10:44 AM ET
Stryker lowers 2026 guidance after slowdown in hip, knee procedures
MedTech Dive · Oct 30, 2026 10:23 AM ET
Truist Trims Price Target on Stryker to $305 From $310, Keeps Hold Rating
MT Newswires · Oct 30, 2026 9:33 AM ET
BMO Capital Adjusts Price Target on Stryker to $309 From $317
MT Newswires · Oct 30, 2026 9:23 AM ET
JNJ's MedTech Segment Disappoints in Q3: Will Growth Rebound in Q4?
Zacks · Oct 30, 2026 9:23 AM ET
SYK Q3 Earnings Call Highlights Softer Demand and Revised Outlook
Zacks · Oct 30, 2026 9:00 AM ET
Deutsche Bank Adjusts Stryker Price Target to $275 From $315, Maintains Hold Rating
MT Newswires · Oct 30, 2026 8:33 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See SYK's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.